Specifically, treatment of head and neck, colorectal, or lung cancers targeting EGFR and HER2/neu has been clinically validated with the use of monoclonal antibodies (mAbs) including cetuximab (EGFR), panitumumab (EGFR), trastuzumab (HER2), or receptor tyrosine kinase inhibitors such as Tarceva (EGFR) or Iressa (EGFR) (5–7). The gene discussed is ERBB2; the disease is lung cancer.